Fremont, CA, October 14, 2009 --(PR.com
)-- Myocardium Technologies, USA, today announced the successful completion of its initial phase of clinical trials on MTMICRO1 and MTECGx products. The primary technology differentiator in MT electrocardiology products is that electrocardiographic evidence of the heart is captured in their original form as they occur retaining all signal components for adult, pediatric, and female population. In addition, such evidence is captured in high resolutions (microvolts and milliseconds at the least) not available in present clinical ECG products.
In the clinical trials, patient data comprised micropotential recordings from normal subjects and patients treated for myocardial infarction. Patient data of subjects who were normal before diagnosis were recorded with the products while patient data with myocardial infarction were selected from the PTB diagnostic ECG database from Physiobank. The Physiobank data were converted into MT format for analysis using the company's MTTools and MTTrials clinical studies software. The MTMICRO1 was validated against its micropotential recording and interpretive analysis capabilities for clinical significance. The MTECGx product in its current version is a cardiac micropotential recorder, and was validated against its micropotential recording capabilities. Information from the database only diagnosed the patients with acute myocardial infarction. In contrast, the microcardiogram report generated by MTMICRO1 from a single channel provided significant clinical information pertaining to heart blocks, localization of the heart blocks, and ST segment elevation/depression, in addition to acute myocardial infarction. Also, the MTMICRO1 detected abnormalities in patients who were otherwise declared normal.
"Cardiovascular disease is the world's number one killer disease", said Suresh Narayanaswamy, CEO and Chief Scientist of Myocardium Technologies. "The lack of tools to make available complete, conclusive clinical evidence of cardiac abnormalities has been a serious deterrent to preventive cardiology. The results from these initial trials will strongly position us for clinical acceptance of our next generation cardiology products."
A pioneer in advanced, non-invasive cardiology products, Myocardium Technologies team includes original contributors of high resolution electrocardiography and electrophysiology. With research and development dating back to 1996, the company intensified its efforts to commercialize its technologies over the past few years. In addition to innovative cardiology products, the company provides product customizations as a service to customers. The MTMICRO1 and MTECGx systems are commercially available only to medical centers and hospitals for research purposes, and are not yet FDA approved.
About Myocardium Technologies:
Myocardium Technologies (http://www.myocardiumtech.com) Myocardium Technologies specializes in advanced, noninvasive cardiovascular products. The company provides products and services for precision diagnosis and treatment of cardiovascular diseases based on its patent pending, next generation cardiovascular technologies. The company's primary focus is to realize products that are either non-existent in today's market or provide substantial improvements over existing systems. The company operates in the following cardiovascular market segments: clinical research, preventive cardiology, diagnosis, and therapy. Myocardium Technologies team includes original inventors and contributors of high resolution electrocardiography and electrophysiology.